CLINICAL_TRIALS ClinicalTrials.gov record update

Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01702428
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:29.850252+00:00
Published At: 2018-06-28T00:00:00+00:00
Record Updated At: 2019-11-25
Results Posted At: 2018-06-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Rubella", "Measles", "Mumps"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-11-25"
protocolSection.identificationModule.nctId: "NCT01702428"
protocolSection.identificationModule.officialTitle: "Consistency Study of GSK Biologicals\u0027 Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck \u0026 Co., Inc.\u0027s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-06-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.